PepGen Inc. (PEPG)

Market Cap	120.60M
Revenue (ttm)	n/a
Net Income (ttm)	-87.23M
Shares Out	32.60M
EPS (ttm)	-2.97
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	17,343
Open	3.600
Previous Close	3.630
Day's Range	3.600 - 3.700
52-Week Range	2.900 - 19.300
Beta	1.56
Analysts	Buy
Price Target	14.67 (+296.49%)
Earnings Date	Nov 7, 2024

About PEPG

PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients. The company is also developing PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 1 clinical trial for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-ED...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 6, 2022
• Employees: 64
• Stock Exchange: NASDAQ
• Ticker Symbol: PEPG
• Website: https://pepgen.com

Analyst Forecast

According to 3 analysts, the average rating for PEPG stock is "Buy." The 12-month stock price forecast is $14.67, which is an increase of 296.49% from the latest price.

Price Target

$14.67

(296.49% upside)

Analyst Consensus: Buy